Trinity Biotech

Trinity Biotech Intangible Assets

The Intangible Assets of Trinity Biotech (TRIB) as of Nov 20, 2026 is 37.50 M USD. In the previous year, Intangible Assets was 16.27 M USD — a change of 130.51% (higher).

Intangible Assets

37.50 MUSD

YoY

130.51%

Last updated:

Intangible Assets of Trinity Biotech is 2024 37.50 M USD. Intangible Assets of Trinity Biotech was 2023 16.27 M USD. It decreases by 130.51% higher compared to the previous year.

The Trinity Biotech Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
64.75 M USD
Jan 1, 2018
52.95 M USD
Jan 1, 2019
31.06 M USD
Jan 1, 2020
33.86 M USD
Jan 1, 2021
35.98 M USD
Jan 1, 2022
22.73 M USD
Jan 1, 2023
16.27 M USD
Jan 1, 2024
37.50 M USD
The Trinity Biotech Intangible Assets history
YEARIntangible AssetsYoY
37.50 MUSD+130.51%
16.27 MUSD-28.43%
22.73 MUSD-36.82%
35.98 MUSD+6.26%
33.86 MUSD+9.00%
31.06 MUSD-41.34%
52.95 MUSD-18.23%
64.75 MUSD-25.80%
87.28 MUSD-19.69%
108.67 MUSD+18.23%
91.92 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Intangible Assets of Trinity Biotech is 37.50 M USD in 2024.

Intangible Assets of Trinity Biotech changed from 16.27 M USD to 37.50 M USD, representing a 130.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech